On April 29, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper), which is being held on May 11 – May 14, 2021, and the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which is being held on June 4 – 8, 2021 (Press release, Phio Pharmaceuticals, APR 29, 2021, View Source [SID1234578803]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Logo – View Source
Details are as follows:
Event:
24th Annual Meeting of the ASGCT (Free ASGCT Whitepaper)
Poster Title:
INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice
Authors:
Benjamin Cuiffo, et al.
Abstract Number:
431
Date/Time:
8:00 AM – 10:00 AM on Tuesday, May 11, 2021
Event:
The 2021 ASCO (Free ASCO Whitepaper) Annual Meeting
Poster Title:
INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice
Authors:
Benjamin Cuiffo, et al.
Abstract Number:
e14537
Date:
Friday, June 4, 2021
Archived versions of the Phio presentations will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).